Globus Medical, Inc.'s stock has surged due to a successful execution of the NuVasive deal and three consecutive guidance hikes, boosting investor confidence and valuation. The $3.1 billion ...

Orthopedic Trauma Devices Market. The Global Orthopedic Trauma Devices Market is projected to be valued at USD 11.39 billion ...

Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Globus Medical, Inc. (NYSE: GMED) has unveiled its financial success for the third quarter of 2024, showcasing notable growth ...

Globus Medical and NuVasive's merger marked its first year on Sept. 1, Globus' CEO Dan Scavilla said in a Nov. 5 earnings call.

The U.S. Food and Drug Administration (FDA) has granted 510 (k) clearance to a standalone lateral lumbar interbody fusion device from the internationally renowned surgeon Randal Betz, M.D.’s company, ...

BofA raised the firm’s price target on Globus Medical (GMED) to $80 from $55 and keeps an Underperform rating on the shares. Globus ...

This beat is partly attributed to the early realization of some of the anticipated $170 million in cost synergies following the integration of NuVasive—a process that has been managed more effectively ...

This beat is partly attributed to the early realization of some of the anticipated $170 million in cost synergies following the integration of NuVasive—a process that has been managed more ...

Globus Medical, Inc. GMED reported third-quarter 2024 adjusted earnings per share (EPS) of 83 cents, which beat the Zacks ...